Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01118741 · ClinicalTrials.gov registry record · NA
Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)
A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT01118741 is a NA study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 19 participants.
The verdict
NCT01118741, a NA study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
disulfiram is a DNA methyltransferase inhibitor that may provide benefit for patients with prostate cancer by restoring tumor suppressor genes.
Interventions
- DRUG Disulfiram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01118741
The ClinicalTrials.gov registry entry for NCT01118741 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Disulfiram is the first listed.
NCT01118741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01118741 about?
NCT01118741 is a clinical study titled "Study of Recurrent Prostate Cancer With Rising Prostate Specific Antigen (PSA)". disulfiram is a DNA methyltransferase inhibitor that may provide benefit for patients with prostate cancer by restoring tumor suppressor genes.
What is the current status of trial NCT01118741?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2010-05. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01118741?
The interventions under investigation include: Disulfiram (DRUG).
Who is sponsoring clinical trial NCT01118741?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.